Orforglipron, a weight-loss pill created by Eli Lilly, has shown promising results in clinical trials, helping participants lose an average of 12.4% of their body weight over 72 weeks. The GLP-1 agonist not only aids in weight loss but also improves other health metrics such as cholesterol, blood pressure, and heart disease risk. With over 3,000 participants involved in the study, Eli Lilly plans to submit orforglipron for regulatory review this year, emphasizing its potential as a convenient alternative to injectable treatments for obesity management.
The drug orforglipron, developed by Eli Lilly, is a GLP-1 agonist that has shown in trials to help patients lose about 12% of their body weight.
In a 72-week study, participants who received the highest dose of orforglipron lost an average of 12.4% of their body weight, compared to just 0.9% for the control group.
Other health improvements noted in users of orforglipron included better cholesterol levels, lower blood pressure, and reduced heart disease risk.
Kenneth Custer expressed confidence that orforglipron can transform obesity care by providing an effective, convenient oral alternative to injectable treatments.
Collection
[
|
...
]